Close

Idifarma appoints new head of site

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

IDIFARMA, a Spanish contract development and manufacturing organisation (CDMO) specialising in niche and highly potent products, has announced the appointment of Alfredo Gómez as its head of site.

In his new role Alfredo Gómez will be responsible for ensuring the company continues to deliver tailored development, manufacturing, and regulatory solutions to pharma companies to speed up their path to market.

With over 20 years’ experience in strategic operations within the pharmaceutical industry, Alfredo has joined the company from his most recent position at Praxis Pharmaceutical, where he was Site Director for almost a decade.

His experience and expertise will support the planned expansion of the business across European and U.S. markets and in product areas with growing demand like oncology.

Idifarma is a CDMO for niche and highly potent drugs, focusing in oral solids for oncology, and with special capabilities such as spray-drying. The company became one of only three CDMOs worldwide offering this type of spray-drying service and is planning to further invest in this technology.

Commenting on his new role Alfredo Gómez said: “Idifarma is well respected in the industry with an impressive track record of operating with niche, innovative and highly potent oral drugs, and using flexibility and specialisation to meet customer demands. I’m looking forward to contributing to its continued success and future growth.”

Latest stories